文献速递哮喘

布地奈德/福莫特罗维持缓解治疗在青少年哮喘中的应用

Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma.
PubMed 文献 · Eur Respir J · 2018-01-04

该事后分析纳入六项随机双盲试验中的青少年(12-17岁)亚组,评估布地奈德/福莫特罗维持缓解治疗(MART)对持续性哮喘的疗效与安全性。

要点

  • BUD/FORM MART较对照降低青少年首次重度急性发作风险(汇总HR 0.49,95%CI 0.34-0.70)。
  • 青少年按需用药量低于对照,且低于成人,支持MART用于青少年持续性哮喘。

核心结论

  • 布地奈德/福莫特罗维持缓解治疗在青少年持续性哮喘中疗效与安全性良好,与成人报告一致。

研究设计与样本

  • 主要终点为首次重度急性发作时间,次要终点包括重度急性发作次数、哮喘相关症状、夜间觉醒、晨间峰值呼气流速、FEV1、按需用药及ACQ-5评分。

主要发现

  • 青少年中BUD/FORM MART较对照降低首次重度急性发作风险(各研究HR 0.15-1.01;汇总HR 0.49,95%CI 0.34-0.70)。
  • BUD/FORM MART在次要终点上显示类似治疗获益。
  • BUD/FORM MART按需用药量低于对照,且青少年按需用药量低于成人。
  • 治疗耐受性良好。

临床怎么用

  • 青少年持续性哮喘可考虑使用BUD/FORM MART方案,其疗效与安全性数据与成人一致。

局限性

  • 本研究为事后分析,青少年亚组来源于六项随机双盲试验,非独立前瞻性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Asthma control is often suboptimal in adolescents, but few studies have evaluated asthma treatments in this population.This post hoc analysis assessed the efficacy and safety of budesonide/formoterol (BUD/FORM) maintenance and reliever therapy (MART) for treatment of persistent asthma in adolescent (age 12-17 years) subgroups within six randomised, double-blind trials. The primary end-point was time to first severe exacerbation. Secondary end-points included number of severe exacerbations, asthma-related symptoms, night-time awakenings, morning peak expiratory flow, forced expiratory volume in 1 s, as-needed medication use and five-item asthma control questionnaire scores.In adolescents (n=1847), BUD/FORM MART was similar to or more effective than comparators across each of the studies in reducing the risk of a first severe exacerbation (hazard ratios (HR) BUD/FORM MART versus comparators 0.15-1.01; pooled HR 0.49, 95% CI 0.34-0.70), with comparable outcomes to the adult subgroups (n=12 197). Similar treatment benefits for BUD/FORM MART were observed for secondary end-points. As-needed medication use was lower with BUD/FORM MART than comparators, and BUD/FORM as-needed use was lower in adolescents than adults. Treatment was well tolerated.This analysis supports the use of BUD/FORM MART in adolescents with persistent asthma, its efficacy and safety being consistent with that reported for adults.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Jorup C, Lythgoe D, Bisgaard H, et al. Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma. Eur Respir J. 2018. PMID: 29301922. doi:10.1183/13993003.01688-2017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。